<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092220</url>
  </required_header>
  <id_info>
    <org_study_id>Multicenter Study</org_study_id>
    <nct_id>NCT02092220</nct_id>
  </id_info>
  <brief_title>A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas</brief_title>
  <official_title>A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that a wearable bionic pancreas system that automatically
      delivers insulin and glucagon can provide superior regulation of glycemia versus usual care
      for adults with type 1 diabetes.

      Please note that all participants must work or attend school at one of the following
      campuses: Massachusetts General Hospital in Boston, MA; University of Massachusetts Medical
      Center in Worcester, MA; University of North Carolina in Chapel Hill, NC; Stanford University
      in Palo Alto, CA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 11</measure>
    <time_frame>Days 2 to 11 of each period</time_frame>
    <description>Glucose reading were taken every 5 minutes by the CGM. The glucose results on Days 2 to 11 were averaged.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Time Spent With CGMG Concentration &lt; 60 mg/dL During Days 2 to 11</measure>
    <time_frame>Days 2 to 11 of each period</time_frame>
    <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than 60 mg/dL [3.3 millimoles/liter (mmol/L)] during Days 2 to 11 was calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean CGMG Values</measure>
    <time_frame>Day 1 and Days 1 to 11 in each period</time_frame>
    <description>Glucose reading were taken every 5 minutes by the CGM. The glucose results on Days 1 and Days 1 to 11 were averaged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time With CGMG Concentration by Ranges During Day 1</measure>
    <time_frame>Day 1 of each period</time_frame>
    <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than the following ranges were calculated:
&lt; 50 mg/dL (2.8 mmol/L) &lt; 60 mg/dL (3.3 mmol/L) &lt; 70 mg/dL (3.9 mmol/L) 70 to 120 mg/dL (3.9 to 6.7 mmol/L) 70 to180 mg/dl (3.9 to 10.0 mmol/L) &gt; 180 mg/dL (10.0 mmol/L) &gt; 250 mg/dL (13.9 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time With CGMG Concentration by Ranges During Days 1 to 11</measure>
    <time_frame>Days 1 to 11 of each period</time_frame>
    <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than the following ranges were calculated:
&lt; 50 mg/dL (2.8 mmol/L) &lt; 70 mg/dL (3.9 mmol/L) 70 to 120 mg/dL (3.9 to 6.7 mmol/L) 70 to180 mg/dl (3.9 to 10.0 mmol/L) &gt; 180 mg/dL (10.0 mmol/L) &gt; 250 mg/dL (13.9 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time With CGMG Concentration by Ranges During Days 2 to 11</measure>
    <time_frame>Days 2 to 11 of each period</time_frame>
    <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than the following ranges were calculated:
&lt; 50 mg/dL (2.8 mmol/L) &lt; 70 mg/dL (3.9 mmol/L) 70 to 120 mg/dL (3.9 to 6.7 mmol/L) 70 to180 mg/dl (3.9 to 10.0 mmol/L) &gt; 180 mg/dL (10.0 mmol/L) &gt; 250 mg/dL (13.9 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean CGMG &lt; 154 mg/dl</measure>
    <time_frame>Day 1, Days 2 to11, Days 1 to11 of each period</time_frame>
    <description>Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 154 mg/dL was the estimated average glucose corresponding to a Glycosylated Hemoglobin A1C of 7%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycemic Events (&lt; 70 mg/dL, &lt; 60 mg/dL, &lt;50 mg/dL)</measure>
    <time_frame>Days 1-11</time_frame>
    <description>A series of hypoglycemic measurements is defined as a single event until there is a break of ≥ 30 minutes between measurements below the defined thresholds of &lt; 70, &lt; 60, and &lt;50 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days That CGM Was Used by Participants as Part of Their Usual Care</measure>
    <time_frame>Days 1-11 of each period</time_frame>
    <description>The percentage of days that participants reported the CGM device was being worn and working properly is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated Albumin on Day 12</measure>
    <time_frame>Day 12 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,5-anhydroglucitol on Day 12</measure>
    <time_frame>Day 12 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Insulin and Anti-Glucagon Antibodies on Day 12</measure>
    <time_frame>Day 12 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe Hypoglycemic Events</measure>
    <time_frame>11 days of each period</time_frame>
    <description>A severe hypoglycemic event is an event where the participant is unable to self-treat and requires the assistance of another person.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Episodes of Symptomatic Hypoglycemia</measure>
    <time_frame>Day 1, Days 1 to 11 and Days 2 to 11 of each period</time_frame>
    <description>The number of episodes of symptomatic hypoglycemia were reported daily by the participant. The average number of episodes of symptomatic hypoglycemia per day was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Reported Carbohydrate Interventions for Hypoglycemia</measure>
    <time_frame>Day 1, Days 1 to 11 and Days 2 to 11 of each period</time_frame>
    <description>The number of carbohydrate interventions for hypoglycemia were reported daily by the participant. The average number of carbohydrate interventions per day is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Grams of Carbohydrate Taken for Hypoglycemia</measure>
    <time_frame>Day 1, Days 1 to 11 and Days 2 to 11 of each period</time_frame>
    <description>The total grams of carbohydrate taken for hypoglycemia as reported daily by the participant were averaged.
The total number of grams of carbohydrate taken for hypoglycemia were reported daily by the participant. The total number of grams of carbohydrate taken are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Total Daily Dose</measure>
    <time_frame>Day 1, Days 1 to 11, Days 2 to 11 of each period</time_frame>
    <description>Insulin total daily dose is reported in units per kilogram per day (U/kg/day).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Total Daily Dose Levels in the Bionic Pancreas Arm</measure>
    <time_frame>Day 1, Days 2 to 11, Days 1 to 11 of each period</time_frame>
    <description>Glucagon dose level is reported in micrograms per kilogram of body mass per day (µg/kg/day).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Glucose Target Set by User (Time-weighted Average Over Study Period) in the Bionic Pancreas Arm</measure>
    <time_frame>Day 1, Days 2 to 11, Days 1 to11, Overall, Daytime, Nighttime of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Bionic Pancreas Off-line or Not Functioning Properly</measure>
    <time_frame>11 days</time_frame>
    <description>Not functioning properly includes issues due to system crash, communication problems between CGM and bionic pancreas, communication problems between bionic pancreas and pumps and pump malfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Nausea Index Score Using a Visual Analog Scale (VAS)</measure>
    <time_frame>Day 1, Days 1 to 11, Days 2 to 11 and each individual day 2 to 11 of each period</time_frame>
    <description>Participants rated their nausea using a 0 to 10 centimeter (cm) VAS where 0=least severe nausea to 10=most severe nausea. The average nausea index scores during Days 1 to 11 and Days 2 to 11 were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline and Day 12 of each period</time_frame>
    <description>The change in body weight collected at Day 12 relative to Baseline. A negative change from Baseline indicates a reduction in body weight and a positive change from Baseline indicates an increase in body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin</measure>
    <time_frame>Baseline and Day 12 of each period</time_frame>
    <description>The change in the value of hemoglobin collected at Day 12 relative to Baseline. A negative change from Baseline indicates a reduction in hemoglobin and a positive change from Baseline indicates an increase in hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Skin Rash</measure>
    <time_frame>11 days of each period</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Reliability Index, Calculated as Percent of Possible Values Actually Recorded by CGM</measure>
    <time_frame>11 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Unscheduled Infusion Set Replacements</measure>
    <time_frame>11 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Daily Basal Insulin Dose</measure>
    <time_frame>Day 1, Days 2 to 11, each individual day 2 to 11 of each period</time_frame>
    <description>Daily basal insulin dose reported in Units per kilogram per day (U/kg/day).</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Daily Bolus Insulin Dose</measure>
    <time_frame>Day 1, Days 1 to 11, Days 2 to 11, each individual day 2 to 11 of each period</time_frame>
    <description>Daily bolus insulin dose reported in Units per kilogram per day (U/kg/day).</description>
  </other_outcome>
  <other_outcome>
    <measure>CGM Mean Absolute Relative Differences (MARD) Versus Time-stamped Blood Glucose (BG) Values From Meter Downloads</measure>
    <time_frame>11 days</time_frame>
    <description>This outcome measure compares the time stamped PG values from the glucose meter to the corresponding CGM glucose value to determine the overall accuracy of the CGM.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <arm_group>
    <arm_group_label>Bionic Pancreas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bionic Pancreas</intervention_name>
    <arm_group_label>Bionic Pancreas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulin pump with or without CGM</intervention_name>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years and have had clinical type 1 diabetes for at least one year

          -  Diabetes managed using an insulin pump for ≥ 6 months

          -  Prescription medication regimen stable for &gt; 1 month (except for medications that will
             not affect the safety of the study and are not expected to affect any outcome of the
             study, in the judgement of the site principal investigator).

          -  Employee or student working or studying during most of the week at one of the
             participating campuses (Massachusetts General Hospital in Boston, MA; University of
             Massachusetts Medical Center in Worcester, MA; University of North Carolina in Chapel
             Hill, NC; Stanford University in Palo Alto, CA)

          -  Lives within a 30 minute drive-time radius of the central monitoring location for one
             of the study sites

          -  Willing to remain within a 60 minute drive-time radius of the central monitoring
             location for one of the study sites during each of the 11-day study arms

          -  Have someone over 18 years of age who lives with them, has access to where they sleep,
             is willing to be in the house when the subject is sleeping, and is willing to receive
             calls from the study staff and check the welfare of the study subject if telemetry
             shows a technical problem or severe biochemical hypoglycemia without subject response
             and the subject does not answer their telephone (up to two individuals can share this
             role, but they must be willing to carefully coordinate with each other and the subject
             so that one of them is clearly designated as having this responsibility at any given
             time)

          -  Willing to wear two infusion sets and continuous glucose monitor (CGM) sensor and
             change sets frequently (at least one new glucagon infusion set daily)

        Exclusion Criteria:

          -  Unable to provide informed consent (e.g. impaired cognition or judgment)

          -  Unable to safely comply with study procedures and reporting requirements (e.g.
             impairment of vision or dexterity that prevents safe operation of the bionic pancreas,
             impaired memory, unable to speak and read English)

          -  Current participation in another diabetes-related clinical trial that, in the judgment
             of the principal investigator, will compromise the results of this study or the safety
             of the subject

          -  Pregnancy [positive urine human chorionic gonadotropin (HCG)] breast feeding, plan to
             become pregnant in the immediate future, or sexually active without use of
             contraception

          -  Need to go outside of the designated geographic boundaries during either arm of the
             study

          -  Current alcohol abuse (intake averaging &gt; 3 drinks daily in last 30 days), use of
             marijuana within 1 month of enrollment, or other substance abuse (use within the last
             6 months of controlled substances other than marijuana without a prescription)

          -  Unwilling or unable to refrain from drinking more than 2 drinks in an hour or more
             than 4 drinks in a day or use of marijuana during the trial

          -  Unwilling or unable or to avoid use of drugs that may dull the sensorium, reduce
             sensitivity to symptoms of hypoglycemia, or hinder decision making during the period
             of participation in the study (use of beta blockers will be allowed as long as the
             dose is stable and the subject does not meet the criteria for hypoglycemia unawareness
             while taking that stable dose, but use of benzodiazepines or narcotics, even if by
             prescription, may be excluded according to the judgment of the principal investigator)

          -  History of liver disease that is expected to interfere with the anti-hypoglycemia
             action of glucagon (e.g. liver failure or cirrhosis). Other liver disease (i.e. active
             hepatitis, steatosis, active biliary disease, any tumor of the liver, hemochromatosis,
             glycogen storage disease) may exclude the subject if it causes significant compromise
             to liver function or may do so in an unpredictable fashion.

          -  Renal failure on dialysis

          -  Personal history of cystic fibrosis, pancreatitis, pancreatic tumor, or any other
             pancreatic disease besides type 1 diabetes

          -  Any known history of coronary artery disease including, but not limited to, history of
             myocardial infarction, stress test showing ischemia, history of angina, or history of
             intervention such as coronary artery bypass grafting, percutaneous coronary
             intervention, or enzymatic lysis of a presumed coronary occlusion)

          -  Abnormal electrocardiogram (EKG) consistent with coronary artery disease or increased
             risk of malignant arrhythmia including, but not limited to, evidence of active
             ischemia, prior myocardial infarction, proximal left anterior descending coronary
             artery (LAD) critical stenosis (Wellen's sign), prolonged QT interval (&gt; 440 ms).
             Non-specific ST segment and T wave changes are not grounds for exclusion in the
             absence of symptoms or history of heart disease. A reassuring evaluation by a
             cardiologist after an abnormal EKG finding may allow participation.

          -  Congestive heart failure (CHF) [established history of CHF, lower extremity edema,
             paroxysmal nocturnal dyspnea, or orthopnea]

          -  History of transient ischaemic attack (TIA) or stroke

          -  Seizure disorder, history of any non-hypoglycemic seizure within the last two years,
             or ongoing treatment with anticonvulsants

          -  History of hypoglycemic seizures or coma in the last year

          -  History of pheochromocytoma: fractionated metanephrines will be tested in patients
             with history increasing the risk for a catecholamine secreting tumor:

               -  episodic or treatment refractory (requiring 4 or more medications to achieve
                  normotension) hypertension

               -  paroxysms of tachycardia, pallor, or headache

               -  personal or family history of multiple endocrine neoplasia type 2A (MEN 2A),
                  multiple endocrine neoplasia type 2B (MEN 2B), neurofibromatosis, or von
                  Hippel-Lindau disease

          -  History of adrenal disease or tumor

          -  Hypertension with systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 despite
             treatment

          -  Untreated or inadequately treated mental illness (indicators would include symptoms
             such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the
             last year), or treatment with anti-psychotic medications that are known to affect
             glucose regulation.

          -  Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be
             susceptible to radio-frequency (RF) interference

          -  Unable to completely avoid acetaminophen for duration of study

          -  History of adverse reaction to glucagon (including allergy) besides nausea and
             vomiting

          -  Established history of allergy or severe reaction to adhesive or tape that must be
             used in the study

          -  History of eating disorder such as anorexia, bulimia, or diabulemia or omission of
             insulin to manipulate weight

          -  History of intentional, inappropriate administration of insulin leading to severe
             hypoglycemia requiring treatment

          -  Use oral [e.g. thiazolidinediones, biguanides, sulfonylureas, glitinides, dipeptidyl
             peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter 2 (SGLT-2) inhibitors]
             anti-diabetic medications

          -  Lives in or frequents areas with poor Verizon wireless network coverage (which would
             prevent remote monitoring)

          -  Any factors that, in the opinion of the site principal investigator or overall
             principal investigator, would interfere with the safe completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Russell, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (MGH) Diabetes Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, Mondesir D, Esmaeili A, Hartigan C, Thompson MJ, Malkani S, Lock JP, Harlan DM, Clinton P, Frank E, Wilson DM, DeSalvo D, Norlander L, Ly T, Buckingham BA, Diner J, Dezube M, Young LA, Goley A, Kirkman MS, Buse JB, Zheng H, Selagamsetty RR, Damiano ER, Russell SJ. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017 Jan 28;389(10067):369-380. doi: 10.1016/S0140-6736(16)32567-3. Epub 2016 Dec 20. Erratum in: Lancet. 2017 Feb 4;389(10068):e2. Erratum in: Lancet. 2017 Jan 28;389(10067):368.</citation>
    <PMID>28007348</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <results_first_submitted>November 1, 2016</results_first_submitted>
  <results_first_submitted_qc>September 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2017</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven J. Russell, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Bionic Pancreas</keyword>
  <keyword>Insulin</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Continuous Glucose Monitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>48 participants were enrolled in the trial, but only 43 participants actually participated. 2 participants were not eligible and 3 participants were not randomized because target enrollment was already met.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bionic Pancreas Then Usual Care</title>
          <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days in Period 1 followed by Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days in Period 2. There was a 3 to 10-day washout period between periods.</description>
        </group>
        <group group_id="P2">
          <title>Usual Care Then Bionic Pancreas</title>
          <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days in Period 1 followed by Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days in Period 2. There was a 3 to 10-day washout period between periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unrelated Illness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Severe Hypoglycaemia</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Nausea, Anxiety, Inconvenience</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Randomized Participants</title>
          <description>All randomized participants who completed both periods of the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 11</title>
        <description>Glucose reading were taken every 5 minutes by the CGM. The glucose results on Days 2 to 11 were averaged.</description>
        <time_frame>Days 2 to 11 of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 11</title>
          <description>Glucose reading were taken every 5 minutes by the CGM. The glucose results on Days 2 to 11 were averaged.</description>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>milligrams/deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.2" spread="9.9"/>
                    <measurement group_id="O2" value="161.5" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Repeated measures model.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-20.28</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>24.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.00</ci_lower_limit>
            <ci_upper_limit>-12.56</ci_upper_limit>
            <estimate_desc>Bionic Pancreas Arm - Usual Care Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Time Spent With CGMG Concentration &lt; 60 mg/dL During Days 2 to 11</title>
        <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than 60 mg/dL [3.3 millimoles/liter (mmol/L)] during Days 2 to 11 was calculated.</description>
        <time_frame>Days 2 to 11 of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent With CGMG Concentration &lt; 60 mg/dL During Days 2 to 11</title>
          <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than 60 mg/dL [3.3 millimoles/liter (mmol/L)] during Days 2 to 11 was calculated.</description>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.6"/>
                    <measurement group_id="O2" value="1.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Repeated measures model.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean CGMG Values</title>
        <description>Glucose reading were taken every 5 minutes by the CGM. The glucose results on Days 1 and Days 1 to 11 were averaged.</description>
        <time_frame>Day 1 and Days 1 to 11 in each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean CGMG Values</title>
          <description>Glucose reading were taken every 5 minutes by the CGM. The glucose results on Days 1 and Days 1 to 11 were averaged.</description>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.3" spread="17.6"/>
                    <measurement group_id="O2" value="161.9" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.5" spread="10.0"/>
                    <measurement group_id="O2" value="161.7" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time With CGMG Concentration by Ranges During Day 1</title>
        <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than the following ranges were calculated:
&lt; 50 mg/dL (2.8 mmol/L) &lt; 60 mg/dL (3.3 mmol/L) &lt; 70 mg/dL (3.9 mmol/L) 70 to 120 mg/dL (3.9 to 6.7 mmol/L) 70 to180 mg/dl (3.9 to 10.0 mmol/L) &gt; 180 mg/dL (10.0 mmol/L) &gt; 250 mg/dL (13.9 mmol/L)</description>
        <time_frame>Day 1 of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time With CGMG Concentration by Ranges During Day 1</title>
          <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than the following ranges were calculated:
&lt; 50 mg/dL (2.8 mmol/L) &lt; 60 mg/dL (3.3 mmol/L) &lt; 70 mg/dL (3.9 mmol/L) 70 to 120 mg/dL (3.9 to 6.7 mmol/L) 70 to180 mg/dl (3.9 to 10.0 mmol/L) &gt; 180 mg/dL (10.0 mmol/L) &gt; 250 mg/dL (13.9 mmol/L)</description>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 50 mg/dl (2.8 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                    <measurement group_id="O2" value="0.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 60 mg/dL (3.3 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.9"/>
                    <measurement group_id="O2" value="2.3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 70 mg/dl (3.9 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.3"/>
                    <measurement group_id="O2" value="5.0" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 to 120 mg/dL (3.9 to 6.7 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" spread="13.6"/>
                    <measurement group_id="O2" value="28.5" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-180 mg/dl (3.9 to 10.0 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8" spread="11.5"/>
                    <measurement group_id="O2" value="62.1" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 180 mg/dL (10.0 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="11.2"/>
                    <measurement group_id="O2" value="32.9" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 250 mg/dL (13.9 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="7.4"/>
                    <measurement group_id="O2" value="12.3" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time With CGMG Concentration by Ranges During Days 1 to 11</title>
        <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than the following ranges were calculated:
&lt; 50 mg/dL (2.8 mmol/L) &lt; 70 mg/dL (3.9 mmol/L) 70 to 120 mg/dL (3.9 to 6.7 mmol/L) 70 to180 mg/dl (3.9 to 10.0 mmol/L) &gt; 180 mg/dL (10.0 mmol/L) &gt; 250 mg/dL (13.9 mmol/L)</description>
        <time_frame>Days 1 to 11 of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time With CGMG Concentration by Ranges During Days 1 to 11</title>
          <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than the following ranges were calculated:
&lt; 50 mg/dL (2.8 mmol/L) &lt; 70 mg/dL (3.9 mmol/L) 70 to 120 mg/dL (3.9 to 6.7 mmol/L) 70 to180 mg/dl (3.9 to 10.0 mmol/L) &gt; 180 mg/dL (10.0 mmol/L) &gt; 250 mg/dL (13.9 mmol/L)</description>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 50 mg/dl (2.8 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.1"/>
                    <measurement group_id="O2" value="0.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 60 mg/dL (3.3 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.5"/>
                    <measurement group_id="O2" value="1.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 70 mg/dl (3.9 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.4"/>
                    <measurement group_id="O2" value="4.6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 to 120 mg/dL (3.9 to 6.7 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" spread="8.0"/>
                    <measurement group_id="O2" value="27.5" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-180 mg/dl (3.9 to 10.0 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" spread="6.0"/>
                    <measurement group_id="O2" value="61.9" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 180 mg/dL (10.0 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="6.0"/>
                    <measurement group_id="O2" value="33.5" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 250 mg/dL (13.9 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.7"/>
                    <measurement group_id="O2" value="11.0" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time With CGMG Concentration by Ranges During Days 2 to 11</title>
        <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than the following ranges were calculated:
&lt; 50 mg/dL (2.8 mmol/L) &lt; 70 mg/dL (3.9 mmol/L) 70 to 120 mg/dL (3.9 to 6.7 mmol/L) 70 to180 mg/dl (3.9 to 10.0 mmol/L) &gt; 180 mg/dL (10.0 mmol/L) &gt; 250 mg/dL (13.9 mmol/L)</description>
        <time_frame>Days 2 to 11 of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time With CGMG Concentration by Ranges During Days 2 to 11</title>
          <description>Glucose reading were taken every 5 minutes by the CGM.The percentage of time that the glucose concentration was less than the following ranges were calculated:
&lt; 50 mg/dL (2.8 mmol/L) &lt; 70 mg/dL (3.9 mmol/L) 70 to 120 mg/dL (3.9 to 6.7 mmol/L) 70 to180 mg/dl (3.9 to 10.0 mmol/L) &gt; 180 mg/dL (10.0 mmol/L) &gt; 250 mg/dL (13.9 mmol/L)</description>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 50 mg/dl (2.8 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 70 mg/dl (3.9 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.4"/>
                    <measurement group_id="O2" value="4.5" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 to 120 mg/dL (3.9 to 6.7 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" spread="7.8"/>
                    <measurement group_id="O2" value="27.4" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-180 mg/dl (3.9 to 10.0 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4" spread="6.0"/>
                    <measurement group_id="O2" value="61.9" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 180 mg/dL (10.0 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="6.1"/>
                    <measurement group_id="O2" value="33.6" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 250 mg/dL (13.9 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.7"/>
                    <measurement group_id="O2" value="10.9" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean CGMG &lt; 154 mg/dl</title>
        <description>Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 154 mg/dL was the estimated average glucose corresponding to a Glycosylated Hemoglobin A1C of 7%.</description>
        <time_frame>Day 1, Days 2 to11, Days 1 to11 of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean CGMG &lt; 154 mg/dl</title>
          <description>Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 154 mg/dL was the estimated average glucose corresponding to a Glycosylated Hemoglobin A1C of 7%.</description>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 2 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hypoglycemic Events (&lt; 70 mg/dL, &lt; 60 mg/dL, &lt;50 mg/dL)</title>
        <description>A series of hypoglycemic measurements is defined as a single event until there is a break of ≥ 30 minutes between measurements below the defined thresholds of &lt; 70, &lt; 60, and &lt;50 mg/dL.</description>
        <time_frame>Days 1-11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hypoglycemic Events (&lt; 70 mg/dL, &lt; 60 mg/dL, &lt;50 mg/dL)</title>
          <description>A series of hypoglycemic measurements is defined as a single event until there is a break of ≥ 30 minutes between measurements below the defined thresholds of &lt; 70, &lt; 60, and &lt;50 mg/dL.</description>
          <units>hypoglycemic events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;50 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.87"/>
                    <measurement group_id="O2" value="1.0" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;60 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="1.31"/>
                    <measurement group_id="O2" value="2.88" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;70 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="2.4"/>
                    <measurement group_id="O2" value="5.28" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days That CGM Was Used by Participants as Part of Their Usual Care</title>
        <description>The percentage of days that participants reported the CGM device was being worn and working properly is reported.</description>
        <time_frame>Days 1-11 of each period</time_frame>
        <population>All randomized participants who completed both periods of the study. This outcome measure applies only to the Usual Care arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days That CGM Was Used by Participants as Part of Their Usual Care</title>
          <description>The percentage of days that participants reported the CGM device was being worn and working properly is reported.</description>
          <population>All randomized participants who completed both periods of the study. This outcome measure applies only to the Usual Care arm.</population>
          <units>percentage of days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycated Albumin on Day 12</title>
        <time_frame>Day 12 of each period</time_frame>
        <population>No data was collected for Glycated Albumin.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Glycated Albumin on Day 12</title>
          <population>No data was collected for Glycated Albumin.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1,5-anhydroglucitol on Day 12</title>
        <time_frame>Day 12 of each period</time_frame>
        <population>No data was collected for 1,5-anhydroglucitol.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>1,5-anhydroglucitol on Day 12</title>
          <population>No data was collected for 1,5-anhydroglucitol.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Insulin and Anti-Glucagon Antibodies on Day 12</title>
        <time_frame>Day 12 of each period</time_frame>
        <population>No data was collected for Anti-Insulin and Anti-Glucagon Antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Insulin and Anti-Glucagon Antibodies on Day 12</title>
          <population>No data was collected for Anti-Insulin and Anti-Glucagon Antibodies.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe Hypoglycemic Events</title>
        <description>A severe hypoglycemic event is an event where the participant is unable to self-treat and requires the assistance of another person.</description>
        <time_frame>11 days of each period</time_frame>
        <population>All participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Hypoglycemic Events</title>
          <description>A severe hypoglycemic event is an event where the participant is unable to self-treat and requires the assistance of another person.</description>
          <population>All participants who completed both periods of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Episodes of Symptomatic Hypoglycemia</title>
        <description>The number of episodes of symptomatic hypoglycemia were reported daily by the participant. The average number of episodes of symptomatic hypoglycemia per day was calculated.</description>
        <time_frame>Day 1, Days 1 to 11 and Days 2 to 11 of each period</time_frame>
        <population>All participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episodes of Symptomatic Hypoglycemia</title>
          <description>The number of episodes of symptomatic hypoglycemia were reported daily by the participant. The average number of episodes of symptomatic hypoglycemia per day was calculated.</description>
          <population>All participants who completed both periods of the study.</population>
          <units>episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="1.04"/>
                    <measurement group_id="O2" value="1.13" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.56"/>
                    <measurement group_id="O2" value="0.90" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 2 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.54"/>
                    <measurement group_id="O2" value="0.88" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Reported Carbohydrate Interventions for Hypoglycemia</title>
        <description>The number of carbohydrate interventions for hypoglycemia were reported daily by the participant. The average number of carbohydrate interventions per day is reported.</description>
        <time_frame>Day 1, Days 1 to 11 and Days 2 to 11 of each period</time_frame>
        <population>All participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Reported Carbohydrate Interventions for Hypoglycemia</title>
          <description>The number of carbohydrate interventions for hypoglycemia were reported daily by the participant. The average number of carbohydrate interventions per day is reported.</description>
          <population>All participants who completed both periods of the study.</population>
          <units>interventions per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.63"/>
                    <measurement group_id="O2" value="1.29" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.34"/>
                    <measurement group_id="O2" value="0.96" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 2 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.34"/>
                    <measurement group_id="O2" value="0.93" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Grams of Carbohydrate Taken for Hypoglycemia</title>
        <description>The total grams of carbohydrate taken for hypoglycemia as reported daily by the participant were averaged.
The total number of grams of carbohydrate taken for hypoglycemia were reported daily by the participant. The total number of grams of carbohydrate taken are reported.</description>
        <time_frame>Day 1, Days 1 to 11 and Days 2 to 11 of each period</time_frame>
        <population>All participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Grams of Carbohydrate Taken for Hypoglycemia</title>
          <description>The total grams of carbohydrate taken for hypoglycemia as reported daily by the participant were averaged.
The total number of grams of carbohydrate taken for hypoglycemia were reported daily by the participant. The total number of grams of carbohydrate taken are reported.</description>
          <population>All participants who completed both periods of the study.</population>
          <units>grams of carbohydrate per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" spread="11.61"/>
                    <measurement group_id="O2" value="25.61" spread="26.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.04" spread="13.62"/>
                    <measurement group_id="O2" value="34.8" spread="16.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 2 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.27" spread="13.79"/>
                    <measurement group_id="O2" value="34.8" spread="16.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Total Daily Dose</title>
        <description>Insulin total daily dose is reported in units per kilogram per day (U/kg/day).</description>
        <time_frame>Day 1, Days 1 to 11, Days 2 to 11 of each period</time_frame>
        <population>All participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Total Daily Dose</title>
          <description>Insulin total daily dose is reported in units per kilogram per day (U/kg/day).</description>
          <population>All participants who completed both periods of the study.</population>
          <units>U/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.20"/>
                    <measurement group_id="O2" value="0.64" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.15"/>
                    <measurement group_id="O2" value="0.63" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 2 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.15"/>
                    <measurement group_id="O2" value="0.62" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Total Daily Dose Levels in the Bionic Pancreas Arm</title>
        <description>Glucagon dose level is reported in micrograms per kilogram of body mass per day (µg/kg/day).</description>
        <time_frame>Day 1, Days 2 to 11, Days 1 to 11 of each period</time_frame>
        <population>All participants who completed both periods of the study. Results are reported for the Bionic Pancreas period only.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Total Daily Dose Levels in the Bionic Pancreas Arm</title>
          <description>Glucagon dose level is reported in micrograms per kilogram of body mass per day (µg/kg/day).</description>
          <population>All participants who completed both periods of the study. Results are reported for the Bionic Pancreas period only.</population>
          <units>µg/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 2 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glucose Target Set by User (Time-weighted Average Over Study Period) in the Bionic Pancreas Arm</title>
        <time_frame>Day 1, Days 2 to 11, Days 1 to11, Overall, Daytime, Nighttime of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>All randomized participants who completed both periods of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose Target Set by User (Time-weighted Average Over Study Period) in the Bionic Pancreas Arm</title>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, Nighttime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.0" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 to 11, Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.9" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 to 11, Daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.0" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 to 11, Nighttime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.7" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 to 11, Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.8" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 to 11, Daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.9" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 to 11, Nighttime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.6" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Bionic Pancreas Off-line or Not Functioning Properly</title>
        <description>Not functioning properly includes issues due to system crash, communication problems between CGM and bionic pancreas, communication problems between bionic pancreas and pumps and pump malfunction.</description>
        <time_frame>11 days</time_frame>
        <population>All randomized participants who completed both periods of the study. Reported for the Bionic pancreas arm only</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Bionic Pancreas Off-line or Not Functioning Properly</title>
          <description>Not functioning properly includes issues due to system crash, communication problems between CGM and bionic pancreas, communication problems between bionic pancreas and pumps and pump malfunction.</description>
          <population>All randomized participants who completed both periods of the study. Reported for the Bionic pancreas arm only</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Insulin pump Lost Wireless Connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucagon Pump Lost Wireless Connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGM Signal Unavailable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Nausea Index Score Using a Visual Analog Scale (VAS)</title>
        <description>Participants rated their nausea using a 0 to 10 centimeter (cm) VAS where 0=least severe nausea to 10=most severe nausea. The average nausea index scores during Days 1 to 11 and Days 2 to 11 were calculated.</description>
        <time_frame>Day 1, Days 1 to 11, Days 2 to 11 and each individual day 2 to 11 of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Nausea Index Score Using a Visual Analog Scale (VAS)</title>
          <description>Participants rated their nausea using a 0 to 10 centimeter (cm) VAS where 0=least severe nausea to 10=most severe nausea. The average nausea index scores during Days 1 to 11 and Days 2 to 11 were calculated.</description>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="1.54"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.79"/>
                    <measurement group_id="O2" value="0.05" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 2 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.82"/>
                    <measurement group_id="O2" value="0.05" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="1.55"/>
                    <measurement group_id="O2" value="0.08" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="1.47"/>
                    <measurement group_id="O2" value="0.03" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="1.19"/>
                    <measurement group_id="O2" value="0.13" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="1.11"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="1.25"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="1.47"/>
                    <measurement group_id="O2" value="0.03" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="1.49"/>
                    <measurement group_id="O2" value="0.08" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="1.23"/>
                    <measurement group_id="O2" value="0.10" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="1.62"/>
                    <measurement group_id="O2" value="0.08" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="1.45"/>
                    <measurement group_id="O2" value="0.03" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight</title>
        <description>The change in body weight collected at Day 12 relative to Baseline. A negative change from Baseline indicates a reduction in body weight and a positive change from Baseline indicates an increase in body weight.</description>
        <time_frame>Baseline and Day 12 of each period</time_frame>
        <population>All participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight</title>
          <description>The change in body weight collected at Day 12 relative to Baseline. A negative change from Baseline indicates a reduction in body weight and a positive change from Baseline indicates an increase in body weight.</description>
          <population>All participants who completed both periods of the study.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.95"/>
                    <measurement group_id="O2" value="0.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin</title>
        <description>The change in the value of hemoglobin collected at Day 12 relative to Baseline. A negative change from Baseline indicates a reduction in hemoglobin and a positive change from Baseline indicates an increase in hemoglobin.</description>
        <time_frame>Baseline and Day 12 of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin</title>
          <description>The change in the value of hemoglobin collected at Day 12 relative to Baseline. A negative change from Baseline indicates a reduction in hemoglobin and a positive change from Baseline indicates an increase in hemoglobin.</description>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>grams/deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.68"/>
                    <measurement group_id="O2" value="0.14" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Skin Rash</title>
        <time_frame>11 days of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Skin Rash</title>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Reliability Index, Calculated as Percent of Possible Values Actually Recorded by CGM</title>
        <time_frame>11 days</time_frame>
        <population>All randomized participants who completed both periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Reliability Index, Calculated as Percent of Possible Values Actually Recorded by CGM</title>
          <population>All randomized participants who completed both periods.</population>
          <units>percentage of possible values</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" spread="1.4"/>
                    <measurement group_id="O2" value="96.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Unscheduled Infusion Set Replacements</title>
        <time_frame>11 days</time_frame>
        <population>All randomized participants who completed both periods of the study. Glucagon infusion sets are not applicable to the Usual Care arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unscheduled Infusion Set Replacements</title>
          <population>All randomized participants who completed both periods of the study. Glucagon infusion sets are not applicable to the Usual Care arm.</population>
          <units>Infusion Set Relacements</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucagon Unscheduled Infusion Set Replacements</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin Unscheduled Infusion Set Replacements</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Daily Basal Insulin Dose</title>
        <description>Daily basal insulin dose reported in Units per kilogram per day (U/kg/day).</description>
        <time_frame>Day 1, Days 2 to 11, each individual day 2 to 11 of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Basal Insulin Dose</title>
          <description>Daily basal insulin dose reported in Units per kilogram per day (U/kg/day).</description>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>U/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 2 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Daily Bolus Insulin Dose</title>
        <description>Daily bolus insulin dose reported in Units per kilogram per day (U/kg/day).</description>
        <time_frame>Day 1, Days 1 to 11, Days 2 to 11, each individual day 2 to 11 of each period</time_frame>
        <population>All randomized participants who completed both periods of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Bolus Insulin Dose</title>
          <description>Daily bolus insulin dose reported in Units per kilogram per day (U/kg/day).</description>
          <population>All randomized participants who completed both periods of the study.</population>
          <units>U/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 2 to 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.2"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>CGM Mean Absolute Relative Differences (MARD) Versus Time-stamped Blood Glucose (BG) Values From Meter Downloads</title>
        <description>This outcome measure compares the time stamped PG values from the glucose meter to the corresponding CGM glucose value to determine the overall accuracy of the CGM.</description>
        <time_frame>11 days</time_frame>
        <population>All randomized participants who completed both periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Bionic Pancreas</title>
            <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
          </group>
        </group_list>
        <measure>
          <title>CGM Mean Absolute Relative Differences (MARD) Versus Time-stamped Blood Glucose (BG) Values From Meter Downloads</title>
          <description>This outcome measure compares the time stamped PG values from the glucose meter to the corresponding CGM glucose value to determine the overall accuracy of the CGM.</description>
          <population>All randomized participants who completed both periods.</population>
          <units>percent difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="31.4"/>
                    <measurement group_id="O2" value="18.0" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Days 1 to 11</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bionic Pancreas</title>
          <description>Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Steven J Russell</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-1848</phone>
      <email>sjrussell@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

